Loading company…
Daegu-based biopharmaceutical company developing radiotherapy-sensitive drugs to improve cancer treatment outcomes.
VSPharm Tech was founded in 2019 and is based in Daegu, South Korea. The company develops drugs that make tumors more sensitive to radiotherapy, aiming to improve cancer treatment. In September 2025 it raised Series B funding from JCH Investment and Enlight Ventures, and as of 2025 its CEO is Shinyoung Park. Planned uses for the funding include VS-101 clinical trials and recruiting R&D staff.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in